Pregabalin Capsule
Product Images NDC 73190-060

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 73190-060). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (053 50)

Pregabalin Capsules 25 mg oral capsules label by AvKARE. The label states dispensing instructions, storage temperature guidelines, and manufacturer information for Eskayef Pharmaceuticals Limited in Bangladesh. The package contains 500 capsules and includes a barcode and toll-free contact number. The label highlights the 25 mg strength in a pink box and indicates prescription use only.*

FDA Label Image

1 (053 90)

Pregabalin Capsules 25 mg oral dosage form by AvKARE. The label states packaging contains 90 capsules and includes storage instructions, manufacturer details, and a barcode. Label indicates prescription use with pharmacy dispensing information.*

FDA Label Image

1 (054 50)

Pregabalin Capsules 50 mg oral capsules label from AvKARE. The label includes the National Drug Code (NDC) 73190-054-50 and states that each capsule contains 50 mg of pregabalin. It indicates the package contains 500 capsules and is for prescription use only. The label includes storage instructions and manufacturer details from ESKAYEF PHARMACEUTICALS LIMITED, Bangladesh, with AvKARE as the labeler.*

FDA Label Image

1 (054 90)

Label for Pregabalin Capsules 50 mg by AvKARE. The label indicates the product contains 90 capsules for oral use. It includes storage instructions, manufacturer details (SKF Eskayef Pharmaceuticals Limited, Bangladesh), and a barcode. The label cautions pharmacists to dispense the Medication Guide and states the product is prescription-only.*

FDA Label Image

1 (055 50)

Pregabalin Capsules 75 mg oral dosage form label by AvKARE. The label states 500 capsules in the package and provides storage instructions along with manufacturer details including Eskayef Pharmaceuticals Limited. Includes handling instructions and a barcode.*

FDA Label Image

1 (055 90)

Label for Pregabalin Capsules 75 mg by AvKARE. The label includes a barcode and states 90 capsules in the package. It provides storage instructions, dispensing requirements, manufacturer details from SK-F Eskayef Pharmaceuticals in Bangladesh, and contact information for AvKARE in Pulaski, TN.*

FDA Label Image

1 (056 50)

Label for Pregabalin Capsules 100 mg, oral capsules, manufactured by Eskayef Pharmaceuticals Limited and labeled for AvKARE. The label displays dosage, storage instructions, and packaging of 500 capsules. The AvKARE logo and barcode are visible, along with prescribing information and contact details for AvKARE in Pulaski, Tennessee.*

FDA Label Image

1 (056 90)

Pregabalin 100 mg capsules label from AvKARE, containing 90 capsules. The label includes storage instructions, dispensing guidelines, manufacturer and labeler information, and a barcode. The capsules are oral dosage form for prescription use only.*

FDA Label Image

1 (057 50)

Label for Pregabalin Capsules 150 mg by AvKARE. The label states it contains 500 capsules, prescription only. Manufactured by Eskayef Pharmaceuticals Limited in Bangladesh. Storage instructions and pharmacist guidance to dispense the medication guide are included. The label also features a barcode and contact information for AvKARE.*

FDA Label Image

1 (057 90)

Pregabalin Capsules 150 mg oral dosage form in a package containing 90 capsules. The label shows the AvKARE brand, states the product is prescription-only, and includes storage instructions. Manufactured by Eskayef Pharmaceuticals Limited for AvKARE in Pulaski, TN.*

FDA Label Image

1 (058 50)

Pregabalin Capsules 200 mg oral dosage form label from AvKARE. The label includes a quantity of 500 capsules. It specifies storage conditions, manufacturing details by Eskayef Pharmaceuticals in Bangladesh, and provides a barcode and contact information for AvKARE in Pulaski, TN.*

FDA Label Image

1 (058 90)

Pregabalin Capsules 200 mg oral capsules in a package label by AvKARE. The label specifies 90 capsules per container, with instructions for pharmacist dispensing and storage conditions at 20° to 25°C. The label includes the NDC 73190-058-90 and manufacturing information for AvKARE, TN, and Eskayef Pharmaceuticals in Bangladesh.*

FDA Label Image

1 (059 50)

Label for Pregabalin Capsules 225 mg by AvKARE. The label indicates a package size of 500 capsules and includes storage instructions, manufacturer and distributor details, a barcode, and a note that the product is prescription only. The label highlights dispensing the accompanying Medication Guide to patients.*

FDA Label Image

1 (059 90)

Pregabalin Capsules 225 mg oral capsules label from AvKARE. The label states the product contains 225 mg of pregabalin per capsule and includes storage instructions (20° to 25°C, excursions permitted between 15° to 30°C). The package contains 90 capsules and is marked Rx Only. Manufactured by Eskayef Pharmaceuticals Limited in Bangladesh for AvKARE in Pulaski, TN. Includes a barcode and instructions to dispense the Medication Guide to patients.*

FDA Label Image

1 (060 50)

Label for Pregabalin Capsules 300 mg, manufactured by Eskayef Pharmaceuticals Limited and labeled by AvKARE. The label states the product is a prescription drug with 500 capsules in the container. It includes storage instructions, manufacturing location in Bangladesh, and a barcode. Dosage directions and safety container information are also noted.*

FDA Label Image

1 (060 90)

Pregabalin Capsules 300 mg oral capsules label from AvKARE, containing 90 capsules. The label indicates the product is prescription only, with usage and storage instructions. It includes manufacturer details for SK+F Eskayef Pharmaceuticals Limited in Bangladesh, and states packaging for AvKARE in Pulaski, TN. The NDC is 73190-060-90.*

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of pregabalin, showing its molecular layout including an amino group (NH2) and a carboxylic acid group (CO2H). The structure depicts its stereochemistry, highlighting its chiral center.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 25 mg, 100 mg, and 200 mg taken three times a day compared to placebo. The graph shows four lines representing these groups and their corresponding improvement trends over a range of pain improvement percentages.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing percent improvement in pain from baseline on the x-axis with percent of patients improved on the y-axis. Two lines are shown: one for Pregabalin 100 mg three times a day and another for placebo. The graph indicates higher patient improvement percentages for Pregabalin compared to placebo across varying levels of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph showing the percentage of patients improved relative to the percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and a placebo group. The y-axis indicates the percent of patients improved, while the x-axis indicates the percent improvement in pain from baseline.*

FDA Label Image

Figure 4 (Pregabalin 05)

Line graph displaying the percent of patients improved (y-axis) versus percent improvement in pain from baseline (x-axis). It compares three groups: Pregabalin 200 mg three times a day (solid line), Pregabalin 100 mg three times a day (dashed line), and placebo (dotted line). Vertical lines highlight percent improvement thresholds at 30 and 50 percent.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line chart comparing the percent of patients improved against percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis represents percent improvement in pain from baseline (0-100%), and the y-axis represents percent of patients improved (0-100%). Three lines show trends for each treatment group, with vertical markers at approximately 30% and 50% improvement.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar chart displaying responder rates (%) from two studies, E1 and E3, by treatment groups and dosages including placebo and various daily doses of Pregabalin. The x-axis represents dose groups with BID or TID dosing labels, and the y-axis shows responder rates from 0% to 60%. Numeric responder rates are shown above each bar.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph depicting seizure reduction as median percent change from baseline versus dose in mg/day for Pregabalin based on multiple studies. The x-axis represents Pregabalin dose ranging from 0 to 600 mg/day, the y-axis shows seizure reduction percentage from -10 to 60. Four study groups are plotted with different symbols showing dose-dependent seizure reduction with statistical significance indicated by p-values below 0.0001 or 0.0007 where applicable.*

FDA Label Image

Figure 8 (Pregabalin 09)

Bar chart depicting responder rates (%) for Pregabalin at different dosages compared to placebo. The X-axis shows placebo, 2.5 mg/kg/day, and 10 mg/kg/day groups, with sample sizes of 93, 103, and 96 respectively. The Y-axis indicates responder rates ranging from 0 to 60%, with bars showing 22.6% for placebo, 29.1% for 2.5 mg/kg/day, and 40.6% for 10 mg/kg/day dosing.*

FDA Label Image

Figure 9 (Pregabalin 10)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, showing trends in patient improvement across varying pain reduction percentages.*

FDA Label Image

Figure 10 (Pregabalin 11)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR (loss of therapeutic response) over 180 days between Pregabalin and placebo groups. The solid line represents Pregabalin, showing a higher percentage of subjects maintaining without LTR over time compared to the dashed line for placebo.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 12 between Pregabalin and placebo groups. The x-axis represents percent improvement intervals from 0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100. The solid line represents Pregabalin, and the dashed line represents placebo, indicating a higher percentage of subjects improved with Pregabalin across most intervals.*

FDA Label Image

Figure 12 (Pregabalin 13)

A line graph comparing the percent of subjects improved from baseline to week 16 based on BOCF (baseline observation carried forward). The x-axis shows percent improved from 0% to 100%, and the y-axis shows percent of subjects improved from 0% to 100%. Two lines represent Pregabalin (solid line) and Placebo (dashed line), illustrating a higher percentage of improvement with Pregabalin compared to Placebo over the range.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.